TELA Bio Statistics
Total Valuation
TELA Bio has a market cap or net worth of $36.44 million. The enterprise value is $52.76 million.
Important Dates
The last earnings date was Tuesday, May 12, 2026, after market close.
| Earnings Date | May 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TELA Bio has 44.77 million shares outstanding. The number of shares has increased by 48.21% in one year.
| Current Share Class | 44.77M |
| Shares Outstanding | 44.77M |
| Shares Change (YoY) | +48.21% |
| Shares Change (QoQ) | +10.78% |
| Owned by Insiders (%) | 7.47% |
| Owned by Institutions (%) | 22.90% |
| Float | 20.01M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.45 |
| Forward PS | 0.41 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.65 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.61
| Current Ratio | 3.61 |
| Quick Ratio | 2.76 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.56 |
Financial Efficiency
Return on equity (ROE) is -616.62% and return on invested capital (ROIC) is -37.76%.
| Return on Equity (ROE) | -616.62% |
| Return on Assets (ROA) | -28.72% |
| Return on Invested Capital (ROIC) | -37.76% |
| Return on Capital Employed (ROCE) | -64.94% |
| Weighted Average Cost of Capital (WACC) | 9.70% |
| Revenue Per Employee | $370,706 |
| Profits Per Employee | -$182,752 |
| Employee Count | 218 |
| Asset Turnover | 1.10 |
| Inventory Turnover | 2.03 |
Taxes
In the past 12 months, TELA Bio has paid $238,000 in taxes.
| Income Tax | 238,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -43.47% in the last 52 weeks. The beta is 1.30, so TELA Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.30 |
| 52-Week Price Change | -43.47% |
| 50-Day Moving Average | 0.78 |
| 200-Day Moving Average | 1.12 |
| Relative Strength Index (RSI) | 45.93 |
| Average Volume (20 Days) | 233,265 |
Short Selling Information
The latest short interest is 765,765, so 1.71% of the outstanding shares have been sold short.
| Short Interest | 765,765 |
| Short Previous Month | 756,594 |
| Short % of Shares Out | 1.71% |
| Short % of Float | 3.83% |
| Short Ratio (days to cover) | 4.12 |
Income Statement
In the last 12 months, TELA Bio had revenue of $80.81 million and -$39.84 million in losses. Loss per share was -$0.80.
| Revenue | 80.81M |
| Gross Profit | 54.73M |
| Operating Income | -33.81M |
| Pretax Income | -39.60M |
| Net Income | -39.84M |
| EBITDA | -32.81M |
| EBIT | -33.81M |
| Loss Per Share | -$0.80 |
Full Income StatementBalance Sheet
The company has $39.54 million in cash and $55.87 million in debt, with a net cash position of -$16.33 million or -$0.36 per share.
| Cash & Cash Equivalents | 39.54M |
| Total Debt | 55.87M |
| Net Cash | -16.33M |
| Net Cash Per Share | -$0.36 |
| Equity (Book Value) | -5.20M |
| Book Value Per Share | -0.12 |
| Working Capital | 46.47M |
Full Balance SheetCash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 995,500 |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
Gross margin is 67.72%, with operating and profit margins of -41.84% and -49.30%.
| Gross Margin | 67.72% |
| Operating Margin | -41.84% |
| Pretax Margin | -49.00% |
| Profit Margin | -49.30% |
| EBITDA Margin | -40.60% |
| EBIT Margin | -41.84% |
| FCF Margin | n/a |
Dividends & Yields
TELA Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -48.21% |
| Shareholder Yield | -48.21% |
| Earnings Yield | -109.33% |
| FCF Yield | n/a |
Analyst Forecast
The average price target for TELA Bio is $2.25, which is 176.41% higher than the current price. The consensus rating is "Buy".
| Price Target | $2.25 |
| Price Target Difference | 176.41% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
